Andere talen G1 Therapeutics, Inc.

Aandelen

GTHX

US3621LQ1099

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,99 ^USD	-4,77%		-6,78%	+30,82%

28/02	G1 Therapeutics, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
28/02	G1 THERAPEUTICS, INC. : Wedbush herhaalt koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024	17/04
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference	04/04
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/04
G1 THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	04/03
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/03
G1 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q4 Revenue $14.9M	28/02
G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024	28/02
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	28/02
G1 Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	27/02
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024	15/02
Top Midday Decliners	13/02
Caution Ahead of Key Inflation Data Weighs on Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	13/02
G1 Therapeutics Gets Nod for Continuing Breast Cancer Study But CEO Notes Lack of 'Positive Interim Analysis'; Shares Drop Premarket	13/02
G1 Therapeutics Gets Continuation Recommendation From Data Monitoring Committee for Phase 3 Breast Cancer Study	13/02
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee	12/02
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee	12/02
Life Sciences Ontario Announces Recipients of 2024 LSO Awards	16/01
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference	08/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen G1 Therapeutics, Inc.

Aandelen

GTHX

US3621LQ1099

Andere talen

Filters